Aspinall is a healthcare industry leader and pioneer with a commitment to active civic involvement. Aspinall is Co-Founder and Managing Director of BlueStone Venture Partners LLC.  BlueStone, a premier venture firm investing in life sciences based technology and innovation companies in the US Southwest.  Aspinall is also CEO of Health Catalysts, an investment and advisory firm dedicated to the growth of new healthcare companies. The firm’s focus is health information technology and diagnostics firms, publishing the popular Health Catalysts Diagnostics Year in Review.  

Aspinall is a member of the Board of Directors of Allscripts (MDRX), Orasure (OSUR), Abcam plc (ABC), 3Scan, Blue Cross Blue Shield Arizona and Castle Biosciences.

Aspinall is the former President and CEO of Ventana Medical Systems, a billion dollar division of The Roche Group, worldwide leader in development and commercialization of tissue-based cancer diagnostics and digital imaging. At Ventana, with her world class team, she led the company to new financial success, more than two dozen major instrument and assay launches and global leadership in companion diagnostics.

Previously, Aspinall spent 12 years with Genzyme Corporation as President of Genzyme Genetics and Genzyme Pharmaceuticals. Genzyme Genetics, grew to become the country’s leading diagnostic testing company, was sold to LabCorp for $1 billion in 2010. Aspinall was also Founder and CEO of On-Q-ity, a start-up diagnostic company dedicated to circulating tumor cells.

Aspinall has spearheaded initiatives to educate payers and policymakers on genomics and personalized medicine. She served as an active member of the Health and Human Services Secretary’s Advisory Council on Genetics, Health & Society (SACGHS) in both the Obama and Bush administrations. Aspinall was also a Trustee of the Dana Farber Cancer Institute for 11 years, where she chaired the Trustee Science Committee.

With a passion for education about the importance of diagnostics in healthcare, Aspinall co-founded the International School of Biomedical Diagnostics at Arizona State University, the first and only program dedicated entirely to Diagnostics as an independent discipline. ASU awarded their first Master degrees in Diagnostics in 2015 and has 102 Master’s students matriculating this year.

Aspinall is a frequent national speaker on healthcare related issues. She was named Arizona Biosciences Leader of the Year in 2016 by the Arizona Biotechnology Association and one of “100 Most Inspiring People in Life Sciences” by PharmaVOICE magazine.

Mara started her business career at the strategic consulting firm Bain & Company. She holds an MBA from Harvard Business School and a BA in International Relations from Tufts University.


Andrew More is a Director at BlueStone Venture Partners.

Before joining BlueStone, Andrew was an Investment Fellow at the UVA LVG Seed Fund in Charlottesville, Virginia where he performed diligence on early stage life sciences startups seeking Seed and Series A funding.

Previously, he was a Senior Associate at Tregaron Capital, a Palo Alto based private equity fund, where he executed lower middle-market buyouts across a variety of industries. Andrew also worked for Ernst & Young’s Transaction Support team where he provided financial due diligence and advisory services for middle-market private equity clients.

Andrew received a BSBA in Accounting and Finance from the University of Arizona, a MAcc from the University of Southern California, and an MBA from the University of Virginia Darden School of Business. He is a licensed CPA in the state of California.

Tom Nickoloff, Founder & Managing Director, is responsible for management and strategic planning activities. Mr. Nickoloff, as the founding member of CRCP, has been instrumental in building CRCP into a successful equity platform by leveraging his extensive management and technology experience developed in the Oil and Gas industry. Prior to forming CRCP, Mr. Nickoloff served in an executive management capacity for a number of Oil & Gas related entities, including: Estancia Oil and Gas, LLC, an upstream exploration and production company headquartered in Austin, Texas where Mr. Nickoloff has negotiated several large acquisition and divestiture transactions; and TRNCO Petroleum Corporation, a Geophysical Project Management company based in Midland, Texas where Mr. Nickoloff serves as President and Chief Geophysicist. Mr. Nickoloff has been credited in industry journals, and received awards for, the development, testing and implementation of many new seismic data acquisition methodologies and processing techniques and is considered one of the early adopters and innovators in the 3D seismic industry.

Mr. Nickoloff is a proven technology innovator, successfully recognizing and developing emerging technologies, and has experience building and managing successful business ventures. Mr. Nickoloff earned a B.Sc. in Geophysical Engineering at The Colorado School of Mines.

Mara Aspinall

(520)848-7444

mara.aspinall@BlueStoneVP.com


Tom Nickoloff

(432)553-1119

tom.nickoloff@BlueStoneVP.com


LEADERSHIP TEAM

Andrew More

(520) 405-9256

andrew.more@BlueStoneVP.com